Phase 2
N=38
A Study of IDN-6556 in Subjects With NAFLD and Raised Transaminases
Nonalcoholic Steatohepatitis · Non-alcoholic Fatty Liver Disease
Bottom Line
View on ClinicalTrials.gov: NCT02077374 ↗Enrolled (actual)
38
Serious AEs
5.3%
Results posted
Jul 2016
Primary outcome: Primary: Change in Alanine Aminotransferase (ALT) — -37.8; -14.9 U/L — p=0.0195
Study Design & Population
- Study type
- Interventional
- Phase
- Phase 2
- Interventions
- IDN-6556 (Drug); Placebo (Other)
- Age
- Adult, Older Adult · 18+ yrs
- Sex
- All
- Sponsor
- Conatus Pharmaceuticals Inc.
- Primary completion
- Mar 2015
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Change in Alanine Aminotransferase (ALT) |
-37.8; -14.9 | 0.0195 sig |
| PRIMARY Relative Percent Change in Alanine Aminotransferase (ALT) |
-39.2; -13.9 | — |
| SECONDARY Change in Aspartate Aminotransferase (AST) |
-6.7; -5.2 | 0.8724 |
| SECONDARY Levels of cCK18/M30 |
-183.0; 14.0 | 0.1149 |
| SECONDARY Levels of Caspase 3/7 RLU |
-287.0; 68.0 | 0.1365 |
| SECONDARY Levels of flCK18/M65 |
-296.0; 4.0 | 0.0471 sig |
Summary
The purpose of this study is to determine the safety and efficacy of IDN-6556 compared to placebo in patients with diagnosed fat deposits in their liver (not caused by alcohol) and with abnormal liver tests
Eligibility Criteria
Inclusion Criteria
- Male or female subjects of minimum adult legal age (according to local laws for signing the informed consent document), able to provide written informed consent, and understand and comply with the requirements of the study
- Diagnosis of non-alcoholic fatty liver disease (NAFLD) as evidenced by imaging or other diagnostic assessments
- Alanine aminotransferase (ALT) levels ≥1.5 x ULN on at least two occasions, seven or more days apart, during the Screening period
- alpha-fetoprotein (AFP) ≤ 100 ng/mL
- Hemoglobin ≥10 g/dL, a platelet count ≥ 100 x 10^9/L, and a white blood cell count ≥ 3.0 x 10^9/L
- If on metformin, sulfonylureas, statins, or fibrates, subjects must be on a stable dose of these drugs for at least three months prior to Screening and during the study
Exclusion Criteria
- Known infection with HIV, HCV, or HBV
- Decompensated or severe liver disease as evidenced by one or more of the following:
- Confirmed cirrhosis or suspicion of cirrhosis
- Esophageal varices
- Ascites
- Suspicion of portal hypertension
- Hospitalization for liver disease within 60 days of screening
- Bilirubin >2 x ULN, or ALT or AST > 10 x ULN
- Inflammatory bowel disease
- Diagnosed or suspected systemic lupus erythematosus (SLE) and/or rheumatoid arthritis (RA)
- Hepatocellular carcinoma (HCC) at entry into the study
- History of or active non-liver malignancies other than curatively treated skin cancer (basal cell or squamous cell carcinomas)
- Significant systemic or major illness other than liver disease, including coronary artery disease, cerebrovascular disease, pulmonary disease, renal insufficiency, and/or serious psychiatric disease, that, in the opinion of the Investigator would preclude the subject from participating in and completing the study
- History or presence of alcohol abuse, defined as consumption of more than 210 mL of alcohol per week (the equivalent of 14 4-ounce glasses of wine or 14 12-ounce cans/bottles of beer or wine coolers), or other substance abuse within the prior two years
Data sourced from ClinicalTrials.gov (NCT02077374). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.